196 related articles for article (PubMed ID: 30417746)
21. Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Patel P; Patel VK; Singh A; Jawaid T; Kamal M; Rajak H
Curr Comput Aided Drug Des; 2019; 15(2):145-166. PubMed ID: 29732991
[TBL] [Abstract][Full Text] [Related]
22. Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies.
Patel P; Shrivastava SK; Sharma P; Kurmi BD; Shirbhate E; Rajak H
J Biomol Struct Dyn; 2024; 42(1):362-383. PubMed ID: 36995068
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment.
Elmezayen AD; Al-Obaidi A; Yelekçi K
J Mol Graph Model; 2021 Jul; 106():107937. PubMed ID: 34049193
[TBL] [Abstract][Full Text] [Related]
24. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
[TBL] [Abstract][Full Text] [Related]
25. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
[TBL] [Abstract][Full Text] [Related]
26. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
27. Exploring structural requirements of HDAC10 inhibitors through comparative machine learning approaches.
Bhattacharya A; Amin SA; Kumar P; Jha T; Gayen S
J Mol Graph Model; 2023 Sep; 123():108510. PubMed ID: 37216830
[TBL] [Abstract][Full Text] [Related]
28. Phenolic compounds as histone deacetylase inhibitors: binding propensity and interaction insights from molecular docking and dynamics simulations.
Uba AI; Zengin G
Amino Acids; 2023 May; 55(5):579-593. PubMed ID: 36781452
[TBL] [Abstract][Full Text] [Related]
29. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
[TBL] [Abstract][Full Text] [Related]
30. Identification of potential histone deacetylase1 (HDAC1) inhibitors using multistep virtual screening approach including SVM model, pharmacophore modeling, molecular docking and biological evaluation.
Krishna S; Lakra AD; Shukla N; Khan S; Mishra DP; Ahmed S; Siddiqi MI
J Biomol Struct Dyn; 2020 Jul; 38(11):3280-3295. PubMed ID: 31411124
[TBL] [Abstract][Full Text] [Related]
31. Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach.
Anand A; Ghosh P; Singh R; Gajanan Bajad N; Kumar A; Singh SK
J Biomol Struct Dyn; 2024 Jun; 42(9):4679-4698. PubMed ID: 37306006
[TBL] [Abstract][Full Text] [Related]
32. Natural Products Extracted from Fungal Species as New Potential Anti-Cancer Drugs: A Structure-Based Drug Repurposing Approach Targeting HDAC7.
Maruca A; Rocca R; Catalano R; Mesiti F; Costa G; Lanzillotta D; Salatino A; Ortuso F; Trapasso F; Alcaro S; Artese A
Molecules; 2020 Nov; 25(23):. PubMed ID: 33255661
[TBL] [Abstract][Full Text] [Related]
33. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors.
Hassanzadeh M; Bagherzadeh K; Amanlou M
J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186
[TBL] [Abstract][Full Text] [Related]
34. Molecular Dynamics Simulations of HDAC-ligand Complexes Towards the Design of New Anticancer Compounds.
Dewaker V; Prabhakar YS
Curr Top Med Chem; 2023; 23(29):2743-2764. PubMed ID: 37779411
[TBL] [Abstract][Full Text] [Related]
35. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
36. Identification of structural fingerprints among natural inhibitors of HDAC1 to accelerate nature-inspired drug discovery in cancer epigenetics.
Sardar S; Jyotisha ; Amin SA; Khatun S; Qureshi IA; Patil UK; Jha T; Gayen S
J Biomol Struct Dyn; 2024 Jul; 42(11):5642-5656. PubMed ID: 38870352
[TBL] [Abstract][Full Text] [Related]
37. A comparative 2D QSAR study on a series of hydroxamic acid-based histone deacetylase inhibitors vis-à-vis comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA).
Bajpai A; Agarwal N; Gupta SP
Indian J Biochem Biophys; 2014 Jun; 51(3):244-52. PubMed ID: 25204088
[TBL] [Abstract][Full Text] [Related]
38. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
39. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking.
Sixto-López Y; Bello M; Correa-Basurto J
J Biomol Struct Dyn; 2019 Feb; 37(3):584-610. PubMed ID: 29447615
[TBL] [Abstract][Full Text] [Related]
40. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
Banerjee S; Baidya SK; Adhikari N; Jha T
SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
